LEO 124249 Ointment in the Treatment of Alopecia Areata
Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata
In the register
The register attaches this trial to Delgocitinib (LEO 124249) (LEO Pharma), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- LEO Pharma
- Participants (registry)
- 40
- Start
- January 2016
- Primary completion
- December 2016
- Study completion
- December 2016
- Last registry update
- March 2025
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: LEO 124249, LEO 124249 Ointment, Vehicle, LEO 124249 Vehicle
Other trials of Delgocitinib (LEO 124249)
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.